Top Clinical Trials companies in Switzerland by Price to Sales Ratio (P/S)
This ranking features the top 1 Clinical Trials companies in Switzerland ranked by Price to Sales Ratio (P/S), averaging a Price to Sales Ratio (P/S) of 24.15, for January 15, 2025.
Switzerland
Clinical Trials
Price to Sales Ratio (P/S)
# |
Name |
Price to Sales Ratio (P/S) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
24.15 |
Jan. 14, 2025 | USD 5.48 | 3.60% |
|
Switzerland |
Frequently Asked Questions
-
Which Clinical Trials company in Switzerland has the highest Price to Sales Ratio (P/S) ?
The Clinical Trials company in Switzerland with the highest Price to Sales Ratio (P/S) is Molecular Partners AG (Swiss Stock Exchange: MOLN.SW) at 24.15.
-
Which Clinical Trials company in Switzerland has the lowest Price to Sales Ratio (P/S) ?
The Clinical Trials company in Switzerland with the lowest Price to Sales Ratio (P/S) is Molecular Partners AG (Swiss Stock Exchange: MOLN.SW) at 24.15.
-
What are the top 10 Clinical Trials companies in Switzerland by Price to Sales Ratio (P/S) ?
The top 10 Clinical Trials companies in Switzerland by Price to Sales Ratio (P/S) are and Molecular Partners AG.
-
What are the bottom 10 Clinical Trials companies in Switzerland by Price to Sales Ratio (P/S) ?
The bottom 10 Clinical Trials companies in Switzerland by Price to Sales Ratio (P/S) are and Molecular Partners AG.